Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study

María Belén Zanchetta(Universidad del Salvador), José Zanchetta(Universidad del Salvador), Juan A. Boailchuk(Instituto de Diagnóstico e Investigaciones Metabólicas), Francesco Massari(Altera (United States)), Fernando Silveira(Instituto de Diagnóstico e Investigaciones Metabólicas), César E. Bogado(Universidad del Salvador)
Osteoporosis International
October 3, 2017
10.1007/s00198-017-4242-6
Cited by 119

Related Papers

Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial
|Journal of Bone and Mineral Research|2008|508
Effects of teriparatide versus alendronate for treating glucocorticoid‐induced osteoporosis: Thirty‐six–month results of a randomized, double‐blind, controlled trial
|Arthritis & Rheumatism|2009|497